Last reviewed · How we verify

Jemperli — Competitive Intelligence Brief

Jemperli (DOSTARLIMAB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Programmed Death Receptor-1 Blocking Antibody [EPC]. Area: Oncology.

marketed Programmed Death Receptor-1 Blocking Antibody [EPC] PD-1 Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Jemperli (DOSTARLIMAB) — GSK. Dostarlimab-gxly binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Jemperli TARGET DOSTARLIMAB GSK marketed Programmed Death Receptor-1 Blocking Antibody [EPC] PD-1 2021-01-01
Penpulimab kcqx PENPULIMAB Akeso Biopharma marketed Pd-1 2025-01-01
Tevimbra TISLELIZUMAB Beigene marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2025-01-01
Loqtorzi TORIPALIMAB Coherus Biosciences Inc marketed Programmed Death Receptor-1 Blocking Antibody [EPC] Pd-1 2024-01-01
Unloxcyt COSIBELIMAB Checkpoint Therapeutics Inc marketed Programmed Death Ligand-1 Blocker [EPC] Pd-1 2024-01-01
Libtayo CEMIPLIMAB Regeneron Pharmaceuticals marketed PD-1 2018-01-01
Keytruda pembrolizumab Merck & Co. marketed Monoclonal antibody; PD-1 inhibitor PD-1 receptor 2014-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Programmed Death Receptor-1 Blocking Antibody [EPC] class)

  1. · 1 drug in this class
  2. BEIGENE · 1 drug in this class
  3. BRISTOL MYERS SQUIBB · 1 drug in this class
  4. BRISTOL-MYERS SQUIBB · 1 drug in this class
  5. Beigene · 1 drug in this class
  6. Beijing Tongren Hospital · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. Coherus Biosciences Inc · 1 drug in this class
  9. GLAXOSMITHKLINE · 1 drug in this class
  10. GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Jemperli — Competitive Intelligence Brief. https://druglandscape.com/ci/dostarlimab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: